Stryker SYK

Reference table

1. What the business is, and the segment data the payload half-carries

Chair and chief executive Kevin A. Lobo; approximately 56,000 employees. Two reportable segments.

Two observations from that table.

First, MedSurg and Neurotechnology is doing the work. It grew 32.2% over two years against Orthopaedics' 9.3% — and it is the larger segment at 62.3%. Stryker is, on the numbers, more a surgical-equipment and neurotechnology company than an orthopaedics company, which is not how it is usually described.

Second, the FY2023 label reads "Orthopaedics and Spine" while FY2024 and FY2025 read "Orthopaedics". Stryker separated its Spine business, so the FY2023 figure is not like-for-like with the years after it, and the 9.3% two-year growth rate above understates the underlying rate by whatever Spine contributed. We flag it rather than computing around it.

The June 2026 quarter, from the 8-K filed 2026-07-30 — and this is the cleanest growth bridge in the batch:

Stryker publishes the full bridge — currency and acquisitions separated from organic — every quarter, which almost no other company in this batch does. The composition matters and it is disclosed too: MedSurg's 9.2% organic was "9.1% from increased unit volume and 0.1% from higher prices", and Orthopaedics' 8.6% was "from increased unit volume" with no price at all. This company grows by selling more, not by charging more, and that is the single most important structural fact about it.

Geography — and the vendor block is missing three-quarters of the company. The FY2025 seg_geo entry reads only Asia Pacific $2,164M, EMEA $3,181M and Other foreign countries $765M, summing to $6,110M against reported revenue of $25,116M. The United States line — $16,943M in FY2024, roughly 75% of revenue — has been dropped. The FY2024 and FY2023 entries are complete. No geographic figure in this dive uses the FY2025 block.

The organisational change, from the 8-K filed 2026-06-26, is worth recording because it signals where management thinks the growth is:

> "In the first quarter 2026 Stryker Corporation announced a change in our organizational structure. Our new Ortho Tech business combines the orthopaedic instruments portfolio from our Instruments business with the Mako and enabling technologies portfolio from our Other Orthopaedics business. By bringing Mako, power tools, cutting accessories, enabling technologies and the teams behind these products together under one business, we are simplifying the customer experience and striving to increase our speed to market through focused innovation."

A company that reorganises around a platform is telling you the platform is the strategy. Note also that no Mako placement, utilisation or procedure figure appears anywhere in this archive.

2. The cyber incident, and the two quarters either side of it

This is the single most important operating event in the file and it is disclosed obliquely — in the chief executive's quotation rather than in a risk factor or a financial note.

From the 8-K filed 2026-07-30:

> "We made significant progress in our recovery from the cyber incident, delivering strong growth in sales, earnings per share and operating cash flow in the second quarter," said Kevin A. Lobo, Chair and CEO. "As we have seen in the past, the resilience of our teams when faced with challenges was once again on display. With our steady cadence of innovation and disciplined operational execution, we enter the second half of 2026 with regained momentum and remain confident in our ability to grow at the high end of MedTech."

The effect is visible in the quarterly series and it is severe:

Read the March 2026 row against every other row in the table. Revenue growth of 2.6% against a run rate of 10-11%; an operating margin of 15.5% against 20.1% in the same quarter a year earlier and 27.3% the quarter before; and an adjusted earnings miss of 12.8%, against beats of 2.0%, 1.9% and 1.6% in the three quarters before it and 5.7% in the quarter after.

And then read the June row. Revenue +9.4%, organic +9.0%, gross margin 68.3% — the highest in the file — operating margin back to 25.2% reported and 27.4% adjusted, GAAP net income up 44.3% and adjusted earnings per share up 17.9%.

Three conclusions.

First, the recovery is real and fast. One damaged quarter, one clean quarter, guidance narrowed rather than cut. That is a good outcome and it should be credited.

Second, the episode is now a permanent feature of the risk assessment. Nothing in a financial statement predicted a 2.6% quarter from a 9% grower, and nothing will predict the next one. The company's disclosure of it is thin — a chief executive quotation, with no quantification of cost, no separate line item and no risk-factor amendment in the extracted filings — and we note that thinness.

Third, the market's memory is longer than one quarter. The stock is down 11.1% over twelve months and 14.8% from its high, having recovered 15.5% in the last three months. The re-rating from the incident is roughly half-reversed.

3. Financials, the balance sheet and the acquisition engine

Revenue has compounded 11.8% a year for five years with gross margin rising from 61.0% to 65.2%. The FY2025 operating margin of 19.5% is the outlier and it is acquisition-related: Inari Medical closed in February 2025, and the 10-Q discloses "a charge" for accelerated vesting of Inari employee awards plus acquisition and integration costs.

The balance sheet, and this is where the acquisitions show up:

Goodwill and intangibles rose $4,722 million in FY2025 and now stand at $24,972 million — 52.2% of total assets — against $22,420 million of equity. Tangible book value is therefore NEGATIVE $3.49 per share against book value of $62.55, and the vendor reports the two as properly distinct.

The acquisition, from the 10-Q:

> "In February 2025 we completed the acquisition of Inari for $80 per share, or an aggregate purchase price of $4,810 [million], net of cash acquired. Inari's product portfolio includes minimally invasive products for the treatment of venous thromboembolism."

Alongside it, Amplitude Vascular Systems, with the 10-Q citing "strategic benefits of expanding our peripheral vascular portfolio." Together they take Stryker into a market it did not previously serve, funded by $2,240 million of incremental debt and cash flow rather than by equity issuance.

Net debt of $12,349 million against roughly $6.7 billion of trailing EBITDA is about 1.85x — the vendor's netDebtToEBITDATTM of 1.847x is consistent. Interest coverage is 8.3x. This is a comfortably investment-grade balance sheet with less headroom than it had a year ago.

Two working-capital items deserve naming. Inventory of $5,310 million represents 223.9 days outstanding — by a wide margin the highest in this batch (Danaher's is 114, KLA's 253 in a different industry). Some of that is structural: implant systems are shipped to hospitals on consignment in multiple sizes, most of which are never used in any given operation. Some of it is a supply chain that has just been through a cyber incident. The distinction matters and the filings do not draw it. And intangiblesToTotalAssetsTTM of 52.8% means more than half the balance sheet is the accounting residue of acquisitions.

The dividend is $3.48 per share, a 1.04% yield at a 35.3% payout of GAAP earnings — a token return, and appropriately so for a company reinvesting in acquisitions. Free cash flow per share is $12.26, giving a 27.4x price-to-free-cash-flow multiple and a 3.65% free-cash-flow yield.

4. Valuation — priced in or room?

At $335.96 (market cap $128.79B, enterprise value approximately $140.3B):

Estimate coverage is good on the near years — 20 analysts on FY2026 and FY2027 revenue, 14 and 15 on EPS — and collapses to 6 on FY2028 EPS. The FY2027 EPS range is $15.534 to $17.081, an 8.9% spread, which is reasonably tight and makes it the right anchor. The FY2026 consensus of $14.999 sits squarely inside management's narrowed guidance of $14.95 to $15.10, so the near year is well anchored and there is no stale-estimate cushion.

est.ebitdaAvg and est.ebitAvg are rejected. In every forward year ebitdaAvg is exactly 22.91% of revenueAvg and ebitAvg is exactly 17.79% — the fixed-ratio fabrication signature. Corroborating defect: netIncomeAvg EXCEEDS ebitAvg in every forward year — $5,721M against $4,852M in FY2026, $6,479M against $5,266M in FY2027, $8,845M against $6,755M in FY2030 — which is impossible for a company paying a 27.6% effective tax rate. All forward valuation uses epsAvg and revenueAvg.

Peer context. The vendor set — Amgen, Boston Scientific, Danaher, Gilead, HCA, McKesson, Medtronic, Pfizer, Sanofi, Vertex — contains two genuine device comparables (Boston Scientific and Medtronic) among pharmaceutical manufacturers and distributors. Danaher is also in this batch and appears here; Intuitive Surgical is also in this batch and does NOT appear, despite being the closest analogue to the Mako franchise. No peer multiples are supplied in the file, so no peer-multiple comparison is drawn.

4a. What today's price assumes (the inversion)

At $335.96 — 22.4x the FY2026 guidance midpoint and 20.0x FY2027 consensus — the price embeds:

• Adjusted EPS of $14.95 to $15.10 in 2026. (Management guidance, half-weighted; consensus at $14.999 is inside it.) The first half delivered $6.29 ($2.60 plus $3.69), so the second half needs approximately $8.71 — implying two quarters averaging $4.36 against the June quarter's $3.69. That is a large second-half weighting, and it is normal for Stryker: the December quarter has been the strongest in each of the last three years ($4.47 in Q4 2025).
• Organic net sales growth of 8.3% to 9.3%. (Management guidance.) The June quarter delivered 9.0% and the first half, including the cyber-damaged March quarter, roughly 5.8%. The full-year figure therefore requires the second half to run at or above 9%.
• Adjusted EPS reaches $16.767 in 2027 — 11.8% growth on 8.5% revenue growth. (Consensus.) The gap is operating leverage, and it is the most fragile assumption in the price, because the June quarter's 27.4% adjusted operating margin is already the high-water mark in this file and the March quarter demonstrated how quickly it reverses.
• No further operational interruption. (Our number.) The cyber incident cost roughly 6.5 percentage points of quarterly revenue growth and 460 basis points of operating margin, and nothing in the filings quantifies it or amends the risk factors. A recurrence is not modelled by anyone.
• The market keeps paying roughly 20x or better on the forward year. (Our number.) At 17x FY2027E the stock is $285; at 24x it is $402. Stryker has traded well above 20x for most of the last decade, so the current multiple is at the low end of its own range rather than at the high end — which is the strongest single argument in the bull case.

4b. The return bridge (why the multiple moves)

Expected return over the next twelve months decomposes as: adjusted EPS growth (+11.8%, from FY2026E $14.999 to FY2027E $16.767) + multiple drift (mild EXPANSION, from 20.0x to roughly 22x on the respective forward year, +10% — offset by the mechanical rolldown) + dividend yield (+1.04%) ≈ +8% to +13%.

Our base assumes a modest re-rating, and the argument for it is specific rather than hopeful: the multiple compressed on an event the company has now demonstrated it has recovered from. Stryker traded at a premium to the medical-device group for a decade on the strength of consistent high-single-digit organic growth; that growth was interrupted for one quarter and has resumed at 9.0%. If the October print confirms it, the reason for the discount goes away.

Sensitivity: if the multiple simply HELD at 20.0x on FY2027E the price would be $336 — spot, exactly. At 22x it is $369; at 24x, $402; at 17x, $285. A base case that needs a 10% re-rating on a stock whose three-month return is already +15.5% is not free, and we name it as the fragile leg.

4c. Variant perception (where we differ, what would surprise)

• We differ from the street by 3.6%, downward — $369 against $382.61 — and with 38 of 51 analysts at buy or better and NO sell ratings, we have no differentiated view. The street's target implies a 22.8x FY2027 multiple; ours implies 22.0x. That is not an edge, and we say so.
• We differ from the vendor data on geography, materially. The FY2025 seg_geo block omits the United States entirely — roughly $19 billion and 75% of revenue — leaving three foreign lines summing to $6,110M against reported revenue of $25,116M. A screen ranking Stryker on geographic exposure using this payload would conclude it is a predominantly non-US business. All geographic figures here come from the FY2024 block and the filings.
• We think the price/volume split is the under-discussed structural fact. MedSurg's June-quarter organic growth was 9.1% volume and 0.1% price; Orthopaedics' was 8.6%, entirely volume. A company with a 65% gross margin and a genuine clinical switching cost that cannot take even one percent of price is telling you something about hospital purchasing power that the margin does not. Watchable number: the price component of organic growth in the 2026-10-29 print. Any move to negative price would be the first evidence of genuine pricing pressure and would attack the operating-leverage assumption in 4a directly.
• We think the cyber-incident disclosure is thin and that this matters more than the incident. The event is acknowledged only in a chief-executive quotation in an earnings release. There is no quantification of cost, no separate line item, and no amended risk factor in the extracted filings. Watchable event: any 8-K, risk-factor amendment or quantified charge relating to the incident. A company that can lose 6.5 points of quarterly revenue growth to an event it discusses in one sentence has a disclosure practice worth monitoring.
• Positive surprise that would force a re-rate: third-quarter organic growth at or above 9% with the adjusted operating margin at or above 27.4%, and full-year guidance raised rather than reaffirmed; or the first disclosure of Mako placement or utilisation data, which would let the market value the robotics franchise separately.
• Negative surprise that would break the thesis: organic growth below 8%, i.e. below management's own floor; adjusted operating margin below 25%; any negative price contribution in either segment; a further acquisition at a scale that pushes net debt above 2.5x EBITDA; a goodwill impairment against the $19,291 million balance; or a second operational interruption.

Synthos fair values

All three anchors are multiples of the FY2027 consensus adjusted EPS distribution (mean $16.767, low $15.534, high $17.081, 15 analysts), cross-checked against management's FY2026 guidance range of $14.95 to $15.10.

• Bear ~$265 — 17.1x the FY2027 consensus LOW of $15.534. Cross-check: 17.6x the FY2026 guidance midpoint; 6.2% BELOW the 52-week low of $282.58. The scenario: organic growth settles below 8%, pricing turns negative, operating leverage reverses, another operational interruption occurs, and the multiple completes its de-rating to a mature device level. −21.1%.
• Base ~$369 — 22.0x the FY2027 consensus MEAN of $16.767. Cross-check: 24.6x the FY2026 guidance midpoint; 19.8x FY2028E; enterprise value of $153.0B on FY2027E revenue of $29.6B is 5.17x sales; 6.4% below the 52-week high of $394.34. Sensitivity, stated openly: 20.0x — today's multiple, HELD — gives $336, which is spot EXACTLY; 24x gives $402. The scenario: the recovery holds, guidance is met, organic growth stays near 9%, and the multiple partially reverses its cyber-incident de-rating. +9.8%.
• Bull ~$440 — 25.8x the FY2027 consensus HIGH of $17.081. Cross-check: 23.6x FY2028E; 11.6% above the 52-week high; 15.0% above the street's consensus target. The scenario: organic growth accelerates above 9.5%, the adjusted operating margin passes 28%, Mako disclosure arrives, and Stryker re-rates back to the premium it carried before the interruption. +31.0%.

Base is 9.8% above spot; asymmetry roughly 1.47:1 to the upside (21.1% down, 31.0% up), plus a 1.04% dividend. That is an unremarkable payoff ratio on a genuinely good business, with a base case that requires a modest re-rating and a conviction lane of exactly nothing.

5. Knowledge base — zero claims, stated as a finding

Direct sweep: ZERO hits. Entity matches: 0. Name-level claims: 0. Broadened sector sweep: 6 text-only hits, all discarded from the conviction pool.

The primary sweep ran entity terms SYK, Stryker, Mako, Inari and Inari Medical, plus a text sweep on Stryker, Mako robot, orthopaedic and orthopedic implant, across all 51,928 distilled claims. It returned exactly zero hits.

The batch brief flagged SYK as a short-ticker homograph risk requiring a case-sensitive check. It did not materialise, and the reason is the same as for CB elsewhere in this batch: no entity in the Synthos knowledge base is tagged SYK or Stryker at all. There is nothing to disambiguate.

A deliberately broadened sweep on stryker, medical device, medtech, knee replacement and hip replacement returned six text-only hits, none entity-tagged to any device manufacturer. Two are worth reporting as sector colour and both are cautionary:

> 2021-10-22 · NEUTRAL · conviction 70 · principle · no entities · speaker: Dev Kantesaria · role: independent · channel: we_study_billionaires

> "Avoid biotech, pharma, medical devices and healthcare — high R&D risk makes them not predictable enough for a five-to-ten-year path to organic growth and free cash flow."

> 2021-10-22 · neutral · conviction 65 · principle · same speaker and session

> "He avoids biotech, pharma, medical devices and all healthcare because high R&D risk makes them not predictable enough for a five-to-ten-year path to organic growth and free cash flow."

This is a named, independent investor excluding the entire category on a stated and testable principle. It is the only substantive outside voice this sweep produced on the sector, it is nearly five years old, and it is negative. We record it because reporting only the flattering absence would be selective — and we note that the principle it states, unpredictability of the five-to-ten-year path, is precisely what the 2026 cyber incident demonstrated.

The remaining four: warren_pies 2023-03-24 (conviction 60) observing that "Healthcare, the second-largest S&P component, [is] starting to come back with strong recent movement in medical device stocks" — a sector-rotation observation naming no company; two lex_fridman claims (2020-12-19 and 2021-10-29) about FDA regulation of rapid COVID diagnostic tests as medical devices, which have nothing to do with orthopaedics or surgical equipment; and one claim about Nvidia, which is pure noise.

Conclusion, stated as a finding. Breadth 0, claim count 0, net conviction none. The Synthos knowledge base contains no claim about Stryker Corporation and no entity-tagged claim about any orthopaedic or surgical-device manufacturer. That is a coverage gap in the ingest source list rather than a judgement about the company — the same gap identified on Chubb elsewhere in this batch, where the insurance sector is likewise uncovered. For this dive the consequence is direct: there is no independent conviction supporting a position on a name whose base case already requires a 10% re-rating, and a name with a 1.47:1 payoff ratio and an empty lane defaults to Watch.

6. Data integrity — what we rejected and why

Six findings. Stryker's file is above average: the segment table reconciles exactly and the tangible-book distinction is correct. The defects are a missing geography and the usual estimate-block fabrication.

1. seg_geo for FY2025 omits the UNITED STATES — roughly 75% of revenue missing. The vendor reports Asia Pacific $2,164M, EMEA $3,181M and Other foreign countries $765M, summing to $6,110M against reported revenue of $25,116M — a $19,006 million shortfall. The FY2024 entry is complete and includes United States $16,943M; FY2023 likewise ($15,257M). This is the same defect class documented on Danaher and Bristol Myers Squibb elsewhere in this batch, and here it is the most severe of the three: three-quarters of the company is absent. All geographic reasoning in this dive uses the FY2024 block and the filings.

2. est.ebitdaAvg and est.ebitAvg carry the fixed-ratio fabrication signature AND are arithmetically impossible — REJECTED. In every forward year ebitdaAvg is exactly 22.91% of revenueAvg and ebitAvg is exactly 17.79%. Additionally netIncomeAvg EXCEEDS ebitAvg in every forward year — $5,721M against $4,852M (FY2026), $6,479M against $5,266M (FY2027), $7,185M against $5,695M (FY2028), $8,845M against $6,755M (FY2030) — net income roughly 20-30% above operating income for a company with a 27.6% effective tax rate, which cannot happen. All forward valuation uses epsAvg and revenueAvg.

3. seg_prod changes a segment label between FY2023 and FY2024 — flagged. The FY2023 entry reads "Orthopaedics and Spine" ($8,662M) while FY2024 and FY2025 read "Orthopaedics" ($9,077M and $9,469M). Stryker separated its Spine business, so the two are not like-for-like and the FY2023-to-FY2025 growth rate of 9.3% understates the underlying rate. We flag it rather than computing around it. The FY2025 entry itself sums to exactly $25,116,000,000 against reported revenue of the same figure, and the vendor's shortened label "MedSurg" corresponds to the company's "MedSurg and Neurotechnology".

4. The FY2028, FY2029 and FY2030 estimate rows rest on 6, 4 and 2 analysts for EPS — EXCLUDED. Against 14 and 15 on FY2026 and FY2027. The FY2030 row, on TWO analysts, supports nothing.

5. returnOnEquityTTM is NULL and epsdiluted is null in every income-statement row — worked around. Return on equity is computed here (trailing net income of $3,729M against average equity near $21,527M is approximately 17.3%); all per-share figures are computed and labelled, and cross-checked against the 8-K's stated reported EPS of $3.30 and adjusted EPS of $3.69 for the June quarter.

6. The cyber incident is disclosed in a chief-executive quotation and nowhere else in the extracted filings. There is no quantification of cost, no separate income-statement line, and no amended risk factor in the 10-Q or 8-K text available here. The effect is nonetheless unmistakable in the March 2026 quarter — revenue growth of 2.6% against a 10-11% run rate and an operating margin of 15.5% against 20.1% a year earlier — and this dive attributes it on the strength of the chief executive's own statement that the second quarter reflected "significant progress in our recovery from the cyber incident." We are inferring the magnitude from the financials, not reading it from a disclosure, and we say so.

Correct and worth recording: seg_prod for FY2025 sums to exactly $25,116,000,000 against reported revenue of the same figure; bookValuePerShareTTM of $62.550 is correctly distinct from tangibleBookValuePerShareTTM of −$3.489, a genuinely negative tangible book properly reported against $24,972M of goodwill and intangibles; netDebtToEBITDATTM of 1.847x is consistent with $12,349M of net debt; intangiblesToTotalAssetsTTM of 52.8%; dividendPayoutRatioTTM of 35.3% on a $3.48 dividend; interestCoverageRatioTTM of 8.30x; and quote.yearHigh/yearLow ($396.86/$281.00) sit within 0.6% of tech.hi52/lo52 ($394.34/$282.58), with tech used throughout.

Non-equity tripwire — checked and passed. SYK is common stock, NYSE-listed. Price of $335.96 is not par-like; beta is 0.778; the dividend is variable and has been raised over many years; volume was 3.04M shares (~$1.0B of turnover); the 52-week band of $282.58 to $394.34 is a 40% range. This is common equity.

7. Technicals

• Price $335.96. −14.8% from the 52-week high of $394.34; +18.9% above the low of $282.58. Position within the annual range: 48th percentile — almost exactly the middle.
• Straddling the averages, in the recovering configuration: +5.6% above a 50-day average of $318.04; −2.0% below a 200-day average of $342.86. The stock is in the process of reclaiming its 200-day rather than failing it.
• RSI 57.7 — constructive without being extended. MACD +5.94 — positive.
• Maximum drawdown from peak over the trailing year: −16.7%, against a current drawdown of −14.8%.
• Relative performance, and the shape is the story: 3-month +15.5% against SPY +7.6% — a 7.9-point outperformance; 6-month −8.7% against SPY +11.1%; 12-month −11.1% against SPY +24.3% and QQQ +30.8% — a 35-point twelve-month deficit. The damage was done in the first quarter of the period and the recovery began roughly three months ago. Stryker is one of only three names in this batch whose three-month return beats the index while its twelve-month return badly lags — a recovering, not a broken, chart.
• Sentiment: 1 strong buy, 37 buy, 13 hold, zero sell across 51 analysts — 75% at buy or better; consensus target $382.61 (+13.9%), median $380, high $465 (+38.4%), low $315 (−6.2%).

Today's move and what it does to the entry

SYK closed 2026-08-04 at $335.96, down 1.54% or $5.24 from $341.20. It opened at $336.04, traded $331.59 to $339.65, and closed mid-range on 3.04M shares. No company-specific filing is dated 2026-08-04; the last was the 2026-07-30 earnings release, five days earlier — a release that beat consensus by 5.7% and narrowed guidance.

The honest read: a 1.5% decline five days after a good print, on a stock still 14.8% below its high, is noise inside a recovery. What it is not is a discount. The stock has already risen 15.5% in three months.

What would change this:

• A price near $300 — roughly 17.9x FY2027E, near the street's low target of $315 and above the 52-week low of $282.58 — which would put our base $369 at a 23% premium. That is 11% below today's close.
• Or the 2026-10-29 print showing organic growth at or above 9% with the adjusted operating margin at or above 27.4%, and guidance raised rather than reaffirmed. At that point the cyber-incident de-rating has no remaining justification and paying 22x is straightforward.

8. Insiders — one officer sold through a plan, and a family director trimmed

The reading is short.

Robert Fletcher, the chief legal officer, sold 4,544 shares across six tranches on a single day at prices between $304.23 and $310.22 — approximately $1.39 million — leaving 10,582 shares. Six tranches at six prices within a $6 band on one day is a single order executing, and it reduced his holding by roughly 30%. Notably, every one of those prices is BELOW today's close of $335.96 — the sales were struck in late May, near the bottom of the recovery.

Ronda Stryker, a director and a member of the founding family, sold 3,707 shares at $315.11, retaining 2,600,815 — a 0.14% reduction of a stake worth approximately $874 million at today's close. At that ratio it is not a transaction with content.

Spencer Stiles, president and chief operating officer, gifted 1,607 shares — a charitable or family transfer, not a sale.

Zero purchases. No F-InKind withholdings anywhere in the file. Two officers selling into the post-incident low is a mild negative and is reported as one, tempered by the fact that both remaining holdings are substantial and the family director's reduction is a rounding error on her position. No transaction by chief executive Kevin Lobo or by the chief financial officer appears anywhere in the file.

9. Verdict, kill-criteria and flip conditions

Watch.

What is genuinely good: June-quarter net sales of $6,589 million, +9.4% reported and +9.0% ORGANIC, with MedSurg and Neurotechnology +9.2% and Orthopaedics +8.6% organic; an adjusted operating margin of 27.4% and adjusted earnings per share up 17.9% to $3.69 against a $3.49 consensus; a 68.3% reported gross margin, the highest in the file; full-year guidance narrowed rather than cut to 8.3-9.3% organic growth and $14.95-15.10 adjusted EPS; revenue compounded 11.8% a year for five years with gross margin rising from 61.0% to 65.2%; interest covered 8.3 times; a 0.778 beta with demand driven by demographics rather than by the cycle; a reorganisation around the Mako robotics platform; and a $4,810 million Inari Medical acquisition extending the company into peripheral vascular, funded from cash flow and debt rather than equity.

What holds it at Watch: a base fair value of $369, 9.8% above spot, with 1.47:1 asymmetry and a base case that requires the multiple to expand from 20.0x to 22.0x — 20.0x held gives exactly today's price; a cyber incident that cut March-quarter revenue growth to 2.6% and the operating margin to 15.5%, disclosed in a single chief-executive sentence with no quantification, no line item and no amended risk factor; organic growth carrying essentially zero price — 0.1% in MedSurg and none in Orthopaedics; tangible book value of negative $3.49 per share with goodwill and intangibles at 52.2% of assets and net debt up $1,881 million to $12,349 million; inventory at 223.9 days, the highest in this batch; a 44% adjusted-to-GAAP earnings gap that grows with each acquisition; a vendor payload missing 75% of revenue from its geographic block; two officers selling and none buying; and — decisively for the tier — a knowledge-base lane of exactly zero claims, whose only sector-level voice argues that medical devices are structurally unpredictable.

The distinction that matters. Stryker is a high-quality compounder that had one bad quarter for a reason outside its control and has visibly recovered from it. The valuation reflects that recovery only partly, which is the bull case, and our base fair value is only 9.8% above spot, which is the reason it is not enough. In the Synthos frame, a name whose base case needs a re-rating, whose payoff ratio is 1.47:1, and whose conviction lane is empty is a Watch with a named entry — and the entry is roughly $300, about 11% below today's close.

Pre-registered KILL criteria — what would take this to Avoid:

• Organic net sales growth below 8% in any quarter, i.e. below the floor of management's own guidance.
• Adjusted operating margin below 25%, which would say the June quarter's 27.4% was a rebound rather than a level.
• Any NEGATIVE price contribution in either segment's organic-growth bridge — the first evidence of genuine hospital pricing pressure on a company that already takes essentially none.
• A second operational interruption, cyber or otherwise, now that the exposure has been demonstrated once.
• A goodwill impairment against the $19,291 million balance, or net debt above 2.5x EBITDA on a further acquisition.
• Inventory rising materially above 224 days, which would suggest the supply-chain normalisation is not happening.

Pre-registered FLIP conditions — what would take this to Buy — Tactical:

• A price near $300 — roughly 17.9x FY2027E, between the street's low target of $315 and the 52-week low of $282.58 — putting our base $369 at a 23% premium. This is the single most likely path to a Buy and it is 11% below today's close.
• The 2026-10-29 print showing organic growth at or above 9% with the adjusted operating margin at or above 27.4% and full-year guidance RAISED, which would remove the entire justification for the cyber-incident de-rating.
• First disclosure of Mako placement or utilisation data, which would let the market value the robotics franchise separately from the implant business — no such figure appears anywhere in this archive.
• A quantified disclosure of the cyber-incident cost with amended risk factors, which would convert an unmeasured exposure into a measured one.
• Any knowledge-base coverage of the medical-device sector appearing. At present the lane is empty and the sector is uncovered, and that alone is worth roughly a tier.

Where SYK fits in the Synthos Framework Portfolio. The medical-technology sleeve, at 0% today with a 2-3% target on a fill near $300 or a confirming October print. On batch overlap, which is unusually relevant here: DHR, ISRG and SYK are all in this batch and all three are in each other's or adjacent peer sets. They are not the same exposure — Danaher sells consumables into laboratories, Intuitive sells a robotic platform and its instruments into general surgery, Stryker sells implants and equipment into orthopaedic theatres — but they share a customer (the hospital), a payer environment and a capital-equipment budget, and holding all three is a sector bet dressed as diversification. Of the three, Intuitive has the highest recurring-revenue share and the deepest drawdown, Stryker has the best near-term operating momentum, and Danaher the slowest growth. Logged as a tracked Synthos call (Watch) as of 2026-08-04 at $335.96.

Single biggest risk: Orthopaedics grows 8.6% on volume with no price. The June-quarter bridge is explicit — MedSurg's organic growth was "9.1% from increased unit volume and 0.1% from higher prices" and Orthopaedics' was "from increased unit volume" alone. A company with a 65% gross margin, a genuine clinical switching cost and a robotics platform that ties surgeons to its implants is nonetheless unable to take one percent of price from its customers. That means every basis point of margin expansion must come from manufacturing and operating leverage — and the March 2026 quarter demonstrated exactly how fast that leverage reverses when volume stumbles: 460 basis points of operating margin gone in one quarter. At 20.0x forward earnings with a base case that needs 22.0x, there is no valuation cushion for a repeat, and consensus FY2027 earnings growth of 11.8% on 8.5% revenue growth is entirely an operating-leverage assumption. That is the $265 bear case, and it requires no competitive event and no acquisition failure — only for hospital purchasing power to keep increasing at the rate it plainly already is.

Provenance & disclosures

• Traceability: ZERO knowledge-base claims name Stryker Corporation out of 51,928 distilled claims (breadth 0, claim count 0, net conviction none). A direct sweep on entity terms SYK, Stryker, Mako, Inari and Inari Medical, plus a text sweep on "Stryker", "Mako robot", "orthopaedic" and "orthopedic implant", returned EXACTLY ZERO hits. The batch brief flagged SYK as a short-ticker homograph risk requiring a case-sensitive check; it did NOT materialise, because no entity in the knowledge base is tagged SYK or Stryker at all — there is nothing to disambiguate, the same result recorded for CB elsewhere in this batch. A deliberately broadened sweep on stryker, medical device, medtech, knee replacement and hip replacement returned six text-only hits, none entity-tagged to any device manufacturer, all discarded from the conviction pool. The two substantive ones are cautionary and are reported rather than suppressed: we_study_billionaires 2021-10-22, speaker Dev Kantesaria, role independent, conviction 70 and 65 in two claims — "Avoid biotech, pharma, medical devices and healthcare — high R&D risk makes them not predictable enough for a five-to-ten-year path to organic growth and free cash flow" — a named independent investor excluding the entire category on a stated principle that the 2026 cyber incident arguably illustrates. The remaining four: warren_pies 2023-03-24 (conviction 60, a healthcare sector-rotation observation naming no company); two lex_fridman claims (2020-12-19, 2021-10-29) about FDA regulation of rapid diagnostic tests; and one claim about Nvidia, pure noise. No concentration sensitivity test is possible on an empty lane. This is a coverage gap in the ingest source list rather than a judgement about the company, and it is a direct input to the Watch verdict.
• Data as-of: fundamentals — organic growth bridges, segment results, guidance, the Inari purchase accounting and the cyber-incident commentary through 2026-06-30, filing-verified from the 10-Q filed 2026-07-31 and the 8-K filed 2026-07-30 which carries the full second-quarter earnings release; the organisational restructuring from the 8-K filed 2026-06-26; annual figures for FY2025 and earlier from the vendor payload cross-checked against the 10-K filed 2026-02-11 · estimates 2026-08-04 · prices 2026-08-04, quote timestamp 1785873720 = 2026-08-04T20:02:00Z ($335.96, −1.54%; 50-DMA $318.04; 200-DMA $342.86; RSI 57.7; MACD +5.94) · knowledge-base claims 2026-08-04. Stryker's fiscal year is the calendar year. All figures come from the Synthos vendor data file for SYK or from the SEC filings in the SYK archive; no figure comes from memory, recall or external retrieval.
• Filing archive contents: 10-K filed 2026-02-11 (fiscal 2025); 10-Q filed 2026-05-11 (March 2026 quarter); 10-Q filed 2026-07-31 (June 2026 quarter — the source of the Inari purchase price and the constant-currency commentary); 8-K filed 2026-07-30, which carries the complete second-quarter earnings release including the organic-growth bridge by segment, the adjusted margin detail and the narrowed FY2026 guidance; 8-K filed 2026-06-26 (the Ortho Tech organisational restructuring); 8-K filed 2026-05-20. All carry preserved [TABLE] statement data.
• Where the filings supplied what the vendor could not, and where they contradicted it (detailed in Section 6): seg_geo for FY2025 omits the UNITED STATES entirely — three foreign lines summing to $6,110M against reported revenue of $25,116M, a $19,006 million / 75% shortfall — with the FY2024 entry complete at United States $16,943M, so all geographic reasoning uses the prior year and the filings; est.ebitdaAvg/ebitAvg rejected for a fixed-ratio signature (exactly 22.91% and 17.79% of revenue in every forward year) and for netIncomeAvg exceeding ebitAvg in every forward year by 20-30%, impossible at a 27.6% tax rate; seg_prod changing a label from "Orthopaedics and Spine" (FY2023) to "Orthopaedics" (FY2024-25) after the Spine separation, making the two-year growth rate not like-for-like; the FY2028, FY2029 and FY2030 EPS rows resting on 6, 4 and 2 analysts and excluded; returnOnEquityTTM NULL and epsdiluted null throughout. The organic-growth bridge by segment, the price-versus-volume split, the adjusted margin detail, the FY2026 guidance, the $4,810 million Inari purchase price and the cyber-incident commentary appear in NO vendor field and come entirely from the filings. Where vendor and filing AGREED — recorded because these defect classes usually bite: seg_prod for FY2025 sums to EXACTLY $25,116,000,000 against reported revenue of the same figure; bookValuePerShareTTM of $62.550 correctly distinct from tangibleBookValuePerShareTTM of −$3.489, a genuinely negative tangible book properly reported; netDebtToEBITDATTM of 1.847x consistent with $12,349M of net debt; interestCoverageRatioTTM of 8.30x; and quote versus tech 52-week ranges within 0.6%.
• Basis note: analyst estimates and company guidance are on adjusted diluted EPS, which excludes acquisition and integration charges, amortisation of purchased intangible assets, structural optimisation and other special charges, goodwill and other impairments, costs to comply with certain medical-device regulations, recall-related matters, and regulatory, legal and tax matters. The gap is large and growing with each acquisition: trailing adjusted EPS of $13.95 against trailing GAAP EPS of $9.72, a 44% difference; June-quarter adjusted EPS of $3.69 against reported $3.30, a 12% difference in a clean quarter. Forward multiples in this dive use consensus adjusted EPS and management's adjusted guidance; the trailing multiple is shown on both bases (24.1x adjusted, 34.5x GAAP) and labelled every time. Organic net sales growth, which this dive uses throughout, is the company's own measure excluding currency and acquisitions and is published with a full bridge every quarter.
• Estimate coverage: 20 analysts on FY2026 and FY2027 revenue, 14 and 15 on the corresponding EPS lines — FY2027 is the anchor for all three fair values, with a range of $15.534 to $17.081, an 8.9% spread; 6 on FY2028 EPS, 4 on FY2029 and 2 on FY2030, all excluded. The FY2026 consensus of $14.999 sits squarely inside management's narrowed guidance of $14.95 to $15.10, so there is no stale-estimate cushion on this name.
• Peer note: the vendor peer set — Amgen, Boston Scientific, Danaher, Gilead, HCA, McKesson, Medtronic, Pfizer, Sanofi, Vertex — contains two genuine device comparables (Boston Scientific, Medtronic) among pharmaceutical manufacturers and distributors. Danaher is also in this batch and appears in this set; Intuitive Surgical is also in this batch and does NOT appear, despite being the closest public analogue to the Mako franchise. No peer multiples are supplied in the file, so no peer-multiple comparison is drawn.
• Fair-value caveat: the $265 / $369 / $440 anchors are multiples of the FY2027 consensus adjusted EPS distribution — 17.1x the low of $15.534, 22.0x the mean of $16.767, and 25.8x the high of $17.081 — cross-checked against management's FY2026 guidance range of $14.95 to $15.10. Stated arithmetic, not a discounted cash flow. The base is sensitivity-disclosed: 20.0x — today's multiple, HELD — gives $336, which is spot EXACTLY; 24x gives $402. The base case therefore REQUIRES a modest multiple expansion, on the specific argument that the de-rating followed an operational incident the company has now demonstrably recovered from; that is the fragile leg and it is named as such in the return bridge and the verdict. Note also that the bear case at $265 sits 6.2% below the 52-week low of $282.58.
• Management-voice note: the FY2026 guidance (organic net sales growth 8.3%-9.3%, adjusted EPS $14.95-$15.10), the chief executive's characterisation of the cyber-incident recovery and of entering the second half "with regained momentum", the statement of confidence in growing "at the high end of MedTech", and the strategic rationale for the Ortho Tech reorganisation are all management's own claims and are half-weighted throughout, labelled wherever quoted.
• Cyber-incident note: the incident is acknowledged only in a chief-executive quotation in the 2026-07-30 earnings release. There is no quantification of cost, no separate income-statement line and no amended risk factor in the filings extracted here. The magnitude used in this dive — approximately 6.5 percentage points of quarterly revenue growth and 460 basis points of operating margin — is INFERRED from the March 2026 quarter's financials against the surrounding run rate, not read from a disclosure, and is labelled as an inference wherever it appears.
• Timing: second-quarter 2026 results were released 2026-07-30, five days before this dive, beating the consensus adjusted EPS estimate by 5.7% ($3.69 against $3.49) with full-year guidance narrowed rather than cut. The next print is 2026-10-29, 86 days away. 2026-08-04 carried no company-specific filing; the stock fell 1.54%.
• Accessibility note: no information in this dive is conveyed by colour. All emphasis is carried by bold text, table structure and explicit labelling.
• Not investment advice. Independent research, educational and informational only, never personalised. No recommendation to buy, sell or hold any security is made to any person.
• Version: 2026-08-04-full.